Company Overview and News
Chicago, IL – June 28, 2018 – Today, Zacks Equity Research discusses the Industry: Life Insurers, including GWG Holdings, Inc. (GWGH - Free Report) , FGL Holdings (FG - Free Report) , American Equity Investment Life Holding Company (AEL - Free Report) , Genworth Financial, Inc. (GNW - Free Report) and Primerica, Inc. (PRI - Free Report) .
ROP WLL LXFR WCG WTW ICHR JOUT PRI TWIN SEDG GWGH GNW FG
Improving rate environment and a favorable employment backdrop should keep the momentum alive in the life insurance space. Given the accelerated pace of rate hikes, life insurers should witness a boost in their investment income. The Federal Reserve’s rate hike in June 2018 marks the seventh increase since December 2015. The Central Bank has announced intentions of two more raises this year with three lined up in 2019 and a couple of in 2020.
PRI GWGH GNW FG
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AMP PRI MORN
Ruane, Cunniff & Goldfarb’s 13F portfolio value decreased ~11% from $12.20B to $10.91B. The number of positions decreased from 66 to 59.
NPSNY BMCH KMX COF.WS RYCEY CAXPF TJX AMZN STCK VIVHY OMC AABA RYCEF BLDR SCHW.PRBCL COF-P IAC WSCC SEQUX BRK.A PRI GOOGL MHK FCAU JD COF.PRG WFCNP COF.PRH FB IBKR WUBA WFC.PRL COF.PRP WFC.PRJ GOOG COF-D WFC.PRT GS COF-C COF-F WFC.PRR WFC.PRQ JEC WFC.PRP WFC.PRO WFC.PRN WFC.PRY COF.PRC WFC.PRX COF.PRD WFC.PRW WFC.PRV CNSWF COF.PRF WFC LBRDB WFC.WS WSBF MA COF LBRDK FWONA W V BKNG SCHW XRAY CACC FWONK WAT LBRDA ORLY
The largest three positions are Alliance Data Systems, Charles Schwab, and Alphabet, and they add up to ~42% of the portfolio.
CCV LBTY NLSN CCZ GOOG AR BAC LBTYK LILAB HCA CMCSK IQV BAM ST SCHW.PRBCL BAMGF BAC CMCSA BBU LBTYB LBTYA SCHW PRI JPM GOOGL CCV.CL LILAK ADS BAMKF ESRX LILA
Good morning. My name is Casey, and I will be your conference operator today. At this time, I would like to welcome everyone to the Primerica Inc. Q1 2018 Earnings Results Conference Call. [Operator Instructions]. Thank you.
Primerica, Inc. (PRI - Free Report) reported first-quarter 2018 operating income of $1.47 per share, missing the Zacks Consensus Estimate of $1.49 by nearly 1.3%. However, the bottom line improved 32.4% year over year on lower effective tax rate (from the legislation of the Tax Cuts and Jobs Act of 2017). Also, ongoing share buybacks offered an additional upside to the bottom line.
TMK LNC TMK.PRC TMK.PRB PRI RGA LNC.WS TMK
The portfolio continues to be very concentrated with the top five positions accounting for ~30% of the 13F portfolio.
FB SERV AMT.PRB AMT.PRA IBKR CMPR GOOG MHFI SPGI AMT CME AGN SSNC AVGO WSH ICE FIS BIDU CBRE TSM ECL ST EFX A BDX VRSN WLTW ZTS AON V 7018 CBG PRI GOOGL CACC ADI BITA BRCM TNET
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to PRI / Primerica, Inc. on message board site Silicon Investor.
as of ET